

British Association of Dermatologists

Comments on the Royal Pharmaceutical Society draft document: Guidance for the prescribers of Specials [2015]

1. We request that the link to the BAD's recommended list of Specials (available from <http://www.bad.org.uk/healthcare-professionals/clinical-standards/specials>) – currently a footnote on P.10 – be given greater prominence, e.g. in Section 4 amongst the links to useful resources.
2. We disagree with the text on p8 after example 1: "Considering all the available options resulted in an equally effective licensed medicine being prescribed for the patient." There is no evidence presented that Psoriderm would work as well. Clinical experience is that refined tars are less effective than unrefined. Better to say that "if the licensed product containing tar did not prove as effective, then sourcing the Special (from a NHS batch manufacturing unit) would be in the patient's best interest".
3. We note some spelling and formatting errors.